Paul Lammers

Paul Lammers, MD, MSc, currently serves as a Biotech Board Director at Salarius Pharmaceuticals since February 2024 and holds a position on the Board of Directors at ImmunoMet Therapeutics, Inc. since February 2019. Previously, Paul led Triumvira Immunologics as Chief Executive Officer from January 2018 to February 2024, focusing on T Cell therapy innovations derived from research at McMaster University. As President & CEO of Mirna Therapeutics from November 2009 to August 2017, efforts were concentrated on enhancing shareholder value through novel cancer treatments. Prior roles included President at Repros Therapeutics, Chief Medical Officer at EMD Serono, and Medical Director at both Organon US and Organon International. Academic qualifications include a Doctor of Medicine and a Master of Science in Reproductive Biology from Radboud University.